Relay Therapeutics Releases Updated Interim Data on RLY-2608, Showing Encouraging Progression-Free Survival in PI3Kα-Mutated Breast Cancer Patients

Relay Therapeutics announced updated interim clinical data for RLY-2608, a PI3Kα inhibitor for PI3Kα-mutated, HR+/HER2- metastatic breast cancer, showing a median progression-free survival (PFS) of 11.0 months in second-line patients when combined with fulvestrant. The company plans to initiate a pivotal Phase 3 trial, ReDiscover-2, in mid-2025, while also progressing combination studies with other therapies and reporting a manageable tolerability profile. Despite the progress, an overall PFS of 10.3 months and the heavily pre-treated patient population suggest cautious interpretation of the drug's potential.

Analysis

Relay Therapeutics (RLAY) presented updated interim clinical data for RLY-2608, its investigational PI3Kα inhibitor, showing a median progression-free survival (PFS) of 11.0 months in second-line (2L) patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer when combined with fulvestrant; notably, within this 2L group, patients with kinase mutations achieved an 18.4-month median PFS versus 8.5 months for non-kinase mutations. These results, consistent with December 2024 data, are accompanied by a manageable tolerability profile, with mostly low-grade treatment-related adverse events and a 92% median dose intensity, supporting the planned initiation of a pivotal Phase 3 trial (ReDiscover-2) in mid-2025. However, the overall median PFS across all evaluated patients at the recommended Phase 3 dose was 10.3 months, a figure that warrants careful interpretation, especially as patients in the current trial arm were heavily pre-treated and considering the historical stagnation in advancing treatments for this CDK4/6-experienced population. While RLY-2608 targets a significant potential market of over 300,000 patients annually in the U.S., it remains pre-commercial. Investor caution is further underscored by significant insider selling, with 43 sales and zero purchases by RLAY insiders in the past six months, including substantial divestments by the CEO, President of R&D, and CFO, totaling millions of dollars. Institutional sentiment appears divided, with 109 firms adding and an equal number decreasing positions last quarter, exemplified by Point72 Asset Management's large new stake contrasted with complete exits by firms like Braidwell LP and Adage Capital Partners.

Key Decisions for Investors

• Investors should closely monitor the initiation and subsequent data readouts from the pivotal Phase 3 ReDiscover-2 trial scheduled for mid-2025, as this will be critical for validating RLY-2608's efficacy, particularly the durability of PFS and safety profile in a broader, potentially less pre-treated, patient population.
• The consistent and substantial insider selling activity by key executives, with zero insider purchases reported in the last six months, warrants significant caution and should be factored into any investment thesis as a potential indicator of management's internal valuation assessment or risk perception.
• Given the mixed clinical signals, such as the encouraging 11.0-month PFS in 2L patients (and 18.4 months in the kinase-mutated 2L subgroup) versus a more modest 10.3-month overall PFS, alongside divergent institutional investor activity, a thorough risk-reward analysis focusing on upcoming catalysts and competitive landscape is essential before committing new capital or adjusting existing positions.